Background: The efficacy of omalizumab (anti-IgE) and increased IgE levels in patients with chronic spontaneous urticaria (CSU) suggest autoallergic mechanisms. Objective: We sought to identify autoallergic targets of IgE in patients with CSU. Methods: Serum samples of patients with CSU together with those of patients with idiopathic anaphylaxis and healthy control subjects (7 of each) were screened for IgE autoantibodies by using an array of more than 9000 proteins. Sera of 1062 patients with CSU and 482 healthy control subjects were used in an IgE-anti-IL-24-specific ELISA to investigate the association of IgE-anti-IL-24 and CSU. Results: By using array analyses, more than 200 IgE autoantigens were found in patients with CSU that were not found in control subjects. Of the 31 IgE autoantigens detected in more than 70% of patients, 8 were soluble or membrane bound and expressed in the skin. Of these, only IgE autoantibodies to IL-24 were found in all patients with CSU. In vitro studies showed IL-24 to release histamine from human mast cells sensitized with purified IgE of patients with CSU but not control subjects. By using ELISA, mean 6 SD levels of IgE-anti-IL-24 were 0.52 6 0.24 IU/mL in patients with CSU and 0.27 6 0.08 IU/mL in control subjects, with 80% of patients with CSU but only 20% of control subjects having levels greater than 0.33 IU/ mL (P < .0001). IgE-anti-IL-24 showed acceptable predictive properties for CSU, with a likelihood ratio of 3.9. Clinically, IgE-anti-IL-24 levels showed an association with disease
It has been 75 years since it was first suggested that the production of wheals in patients with urticaria might have an underlying allergic mechanism.
1 Certainly, the effectiveness of H 1 -antihistamines in patients with urticaria 2 would support this hypothesis, even though no obvious extrinsic allergens have been identified. This prompted Rorsman 3 to suggest urticaria to be an autoallergy (ie, type I hypersensitivity to selfallergens). The involvement of IgE in patients with urticaria was suggested from 2 sources. First is the association of chronic spontaneous urticaria (CSU) with high levels of total IgE and increased levels of IgE directed, for example, against thyroid antigens and double-stranded DNA. [4] [5] [6] Second is the effectiveness of omalizumab (anti-IgE) in relieving the symptoms of CSU. 7 In patients with other autoimmune conditions, such as systemic lupus erythematosus, the disease is complex and characterized by production of autoantibodies to a broad range of self-antigens. 8 For example, in patients with systemic lupus erythematosus, IgE antibodies specific for double-stranded DNA have been suggested to stimulate plasmacytoid dendritic cells, an immune cell linked to viral defense, to secrete substantial amounts of IFN-a. 9 We postulate that CSU is an autoimmune disease in which IgE recognizes several autoantigens that are probably primarily dermal in origin. Low-level diffusion of these into the bloodstream would be consistent with the basopenia seen in patients with CSU. 3, 10 Furthermore, periods of increased local generation of such allergens would explain the localized exacerbations of CSU.
To test this hypothesis, large-scale screening of autoreactive IgE in the serum of patients with CSU was used to explore potential targets of IgE autoantibodies (IgE-AAbs) in patients with this disease. IgE present in sera from patients with idiopathic anaphylaxis (IdA) and healthy subjects was used as a control. The association of the primary IgE autoantibody was further investigated both in vitro and clinically. 
METHODS

Serum from patients with CSU and control subjects
We analyzed 1062 patients with CSU (73% female), 7 patients with IdA (57% female), and 482 healthy control subjects (61% female). There was no significant difference between the ages of patients with CSU (mean 6 SD, 44.0 6 14.7 years), patients with IdA (44.4 6 13 years), and healthy control subjects (46.9 6 16.7 years).
All patients were treated at our specialized outpatient clinic for dermatologic allergology. They were given a diagnosis of CSU or IdA in line with the current World Allergy Organization ''Guidelines for the assessment and management of anaphylaxis'' and the European Academy of Allergy and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum/World Allergy Organization urticaria guidelines, respectively. None of the patients with CSU had concomitant IdA, and none of the patients with IdA had CSU, thus excluding overlap in the patients analyzed by using microarray analyses. We did not systematically assess autoimmune comorbidities in the study subjects.
In our patients with CSU, the mean duration of disease was 5.0 years, and the mean 7-day urticaria activity score (UAS7) 2 was 16.7. Fifty percent of patients with CSU had angioedema, and 26% had positive autologous serum skin test reactions, which were defined as being greater than 2 mm compared with those elicited by the negative control.
Blood was taken from all study subjects, and serum was separated after clot formation without the use of a clotting enhancer. After separation, serum was frozen immediately and stored at 2808C until used for microarray, ELISA, or IgE purification for functional studies.
Ethics statement
Blood samples taken from patients and all material investigated in this study were used after written informed consent, as approved by the ethics committee of the Charit e-Universit€ atsmedizin Berlin (EA1-329-14 and EA1-292-14), according to the Declaration of Helsinki (59th WMA General Assembly, Seoul, Korea; October 2008).
Auto-IgEome analyses using a microarray
One milliliter of serum from 7 patients with CSU, 7 patients with IdA, and 7 healthy control subjects was incubated on a ProtoArray Human Protein Microarray (version 5.1; Thermo Fisher, Waltham, Mass) at room temperature for 1 hour. This microarray contains 9374 unique, full-length human proteins. The slide was then washed 3 times with PBS with 0.05% Tween-20 (TPBS; Sigma, Munich, Germany) and incubated with 1 mL of staining solution for 30 minutes in the dark (1 mg/mL each of mouse anti-human IgGphycoerythrin [clone G18-145] and mouse anti-human IgE-allophycocyanin [clone MHE-18; both from BioLegend, San Diego, Calif]) in 2% human albumin (clinical grade [Baxter, Unterschleißheim, Germany] in TPBS). Thereafter, the slide was washed extensively with TPBS, followed by 3 washes with water and measurement at a resolution of 2 mm in a PowerScanner (Tecan, M€ annedorf, Switzerland). Specificity of mAbs was tested on nonserum-treated chips to remove off-target bindings. The signal was calculated as mean or z scores, and signals corresponding to immunoglobulin-binding proteins (TRIM domain-containing or FcR proteins) were removed.
Quantification of IgE-anti-IL-24 function
The functionality of IgE-anti-IL-24 was tested by using histamine release from peripheral CD34 1 stem cell-derived mast cells (PSCMCs), which were prepared as previously described. 11 Briefly, CD34 1 cells (STEMCELL Technologies, Cologne, Germany) were cultured with rIL-3 and stem cell factor (both from Miltenyi Biotec, Bergisch Gladbach, Germany) for 2 weeks in SFEM medium containing human LDL (STEMCELL Technologies). Beads for IgE purification were prepared with 1 mg of anti-IgE mab (clone MB10-5C4; Miltenyi Biotec) conjugated to NHS-mag Sepharose (GE, Frankfurt am Main, Germany) and blocked with 100 mmol/L ethanolamine in 1 mol/L Tris (pH 8.0; Sigma). Total IgE was purified from 1 L of pooled serum from patients with CSU or healthy subjects by using these beads after 24 hours of incubation at 48C. Beads were washed with TPBS, and IgE was eluted with 0.1 mol/L citrate buffer (Sigma) at pH 2 and stabilized with 1 mol/L Tris (pH 8.0). PSCMCs were diluted to 2 3 10 5 /mL in 10 mL of SFEM medium (STEMCELL Technologies) containing 250 mL (5 10 mg) of total IgE preparation and incubated overnight at 378C.
Ninety-six-well plates were coated overnight at 378C with 0.5 mg of IL-24 (Miltenyi Biotec) per well in carbonate buffer (pH 9). Plates were blocked for 2 hours at room temperature with 2% human serum albumin in PBS. IgEloaded PSCMCs were washed with RPMI (Thermo Fisher) and added to the plates to a final concentration of 80,000 cells per well in 0.2 mL of SFEM medium. In addition to the coated wells, further wells were submitted to antiIgE (1 mg/well), 1% Triton-X, or nothing for 30 minutes at 378C. Thereafter, plates were centrifuged at 400g for 8 minutes to deplete cells. Supernatants J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 3 were stored in 2808C until histamine measurement in a HISTAREADER (Reflab, Copenhagen, Denmark).
IgE-anti-IL-24 measurements by means of ELISA
Sixteen micrograms of anti-IgE (MHE-18; BioLegend) were dispensed in 10 mL of Coating Buffer (0.1 mol/L carbonate [pH 9]; Sigma), and 25 mL of this solution was used per well in a black NUNC Maxi-Sorb 384-well plate (Thermo Fisher) to coat at 48C overnight. After blocking with 2% human serum albumin in TPBS again overnight at 48C, human sera were added from a 96-well plate as four 25 mL/well replicates and incubated at 48C overnight, followed by 3 washes with TPBS and 3 washes with water. Thereafter, 25 mL/well antigen solution containing 4 mg of BHHCT (Sigma) conjugated (molar ratio, 1:30) and europium (Sigma) saturated IL-24 (Miltenyi Biotec) per 10 mL of 50 mmol/L DTPA-purified BSA (PerkinElmer, Waltham, Mass) in 50 mmol/L Tris buffer (pH 8) was added and incubated at 48C for 1 hour. After washing 10 times with water, 25 mL of DELFIA enhancer solution (PerkinElmer) was added to each well. Plates were measured in a Victor V reader (PerkinElmer) with standard settings.
We report mean values of a total of 1062 patients with CSU and 482 healthy control subjects, with each subject tested up to 4 times in 4 independent experiments with similar results.
Calculation of IgE-anti-IL-24 units, fractions, and cutoffs
Recombinant IgE-anti-green fluorescent protein (Bio-Rad Laboratories, Munich, Germany) was used to generate a standard curve to calculate IgE-anti-IL-24 values in international units per milliliter of serum measured by means of ELISA and IgE-anti-IL-24 values in international units per protein spot by using a microarray. The sum of autoreactive IgE, as detected by using the microarray, was calculated based on IgE-anti-IL-24 protein spots, which allowed us to determine the percentage of IgE-anti-IL-24 of all detectable autoreactive IgE. Because of several calculation steps, the values can be viewed as an approximation. Total IgE levels measured by the Central Laboratory of Charit e-Universit€ atsmedizin Berlin were used to calculate the percentage of ELISA-based IgE-anti-IL-24. The cutoff for increased IgE-anti-IL-24 ELISA values was calculated according to the receiver operating characteristic curve by using the Youden index.
Assessment of basophil numbers
Blood basophil numbers were determined by the Central Laboratory of the Charit e-Universit€ atsmedizin Berlin by using an automated hematocytometer.
Statistical analyses
Normal distribution was tested with the D'Agostino-Pearson omnibus test, and an approximately Gaussian distribution served as a basis to perform Student t and ANOVA tests corrected for multiple testing by using the Holm-Sidak method. The null hypothesis of random results was rejected if the P value was very small (ie, P < .05).
RESULTS
Patients with CSU frequently exhibit IgE against many autoantigens
All 7 patients with CSU, patients with IdA, and healthy control subjects exhibited IgE-AAbs against multiple autoantigens, as assessed by using microarray analyses of serum reactivity to 9374 human proteins (Fig 1) . IgE-AAbs from patients with CSU recognized a mean 6 SD of 95 6 66 autoantigens, patients with IdA recognized a mean 6 SD of 105 6 63 autoallergens, and healthy control subjects recognized a mean 6 SD of 28 6 11 autoallergens. The distribution of autoallergens recognized by each group is shown in the Venn diagram (Fig 2 and Tables I and II ) . Of the total 226 autoantigens recognized by IgE (IgE-AAs) from at least 1 patient with CSU, only 4 were also recognized by IgE from a patient with IdA and none by IgE from any healthy control subjects. IgE from patients with CSU was more heterogeneous and recognized more different autoantigens than IgE from patients with IdA (226 vs 161).
Considering the IgE-AAs recognized only by serum from a patient with CSU, Tables I and II show that 222 autoallergens were recognized by at least 1 patient. As the number of patients increased, the number of common autoallergens decreased, so that the IgE of half of the patients reacted to 77 autoantigens, whereas 31 autoallergens were recognized by 71% of patients, and only 3 autoallergens are fully shared autoallergens recognized by all patients with CSU.
Accessibility of CSU-specific IgE-AAbs to autoantigens expressed in the skin
Of the 31 autoantigens to which most (71%) of the patients with CSU had IgE-AAbs, 8 were accessible, 4 were soluble, and 4 were membrane-bound autoallergens. In contrast, the other 23 IgE-AAs were intracellular and therefore are unlikely to be accessible. Of the 8 accessible IgE-AAs, all can be expressed in the skin, but only 1, IL-24, was detected by IgE-AAbs of all 7 patients with CSU (Fig 1) .
IgE-anti-IL-24 is the most abundant IgE-AAb in patients with CSU
In all patients with CSU analyzed by using a protein array, IgE-anti-IL-24 showed the highest serum levels of all IgE-AAbs detected. Up to 1.1% (mean 6 SD, 0.6% 6 0.24%) of the total detectable IgE-AAbs in patients with CSU was IgE-anti-IL-24. IgE-anti-IL-24 serum levels did not correlate with total IgE (r 5 0.002, P 5 .840) or total IgE-AAb levels. None of the 7 patients with CSU had detectable IgG-anti-IL-24 serum levels.
IgE-anti-IL-24 and IL-24 induce mast cell degranulation
PSCMCs were sensitized with purified total IgE from patients with CSU, healthy control subjects, or with purified IgE-anti-IL-24. IL-24 induced degranulation in cells that had been preincubated with purified IgE from patients with CSU but not healthy control subjects (Fig 3, A) . Mast cells also showed degranulation after sensitization with purified IgE-anti-IL-24 and challenge with IL-24 (Fig 3, B) . Fig 3, A) healthy control subjects before stimulation with anti-IgE, coated IL-24, or vehicle as a control. Data shown are mean values of absolute release and SEMs. Spontaneous release was 12%. No specific mast cell degranulation was induced by IL-24 alone. Fig 3, A, shows pooled data from 4 experiments by using the same IgE preparation but different cell donors. Data shown in Fig 3, B, are from one of 3 experiments with similar results. ***P < .005 and ****P < .0001.
FIG 4.
IgE-anti-IL-24 levels are greater and more often increased in patients with CSU compared with those in healthy control subjects. A, Patients with CSU have 2.2-fold higher serum levels of IgE-anti-IL-24, as determined by means of ELISA. Patients with CSU: mean 6 SEM 5 0.5 6 0.2 IU/mL (median, 0.49 IU/mL; range, 0.0-2.3 IU/mL); healthy subjects: mean 6 SEM 5 0.3 6 0.1 IU/mL (median, 0.3 IU/mL; range, 0.1-0.6 IU/mL). The box shows 10% to 90% percentiles. B, Compared with healthy control subjects, patients with CSU exhibit a higher prevalence of increased IgE-anti-IL-24 levels. C, Receiver operating characteristic analyses of ELISA-based measurements show that the cutoff for an increased IgE-anti-IL-24 value is 0.33 IU/mL (dotted line), as determined by using the Youden index, with a specificity of 80% and sensitivity of 80%. All 3 panels show the same data from one representative measurement from 716 patients with CSU and 332 healthy control subjects of 4 independent measurements, with a total of 1062 patients with CSU and 482 healthy control subjects, showing similar results. ***P < .001.
IgE-anti-IL-24 is a sensitive and specific marker of CSU
To further investigate the association of IgE-anti-IL-24 and CSU, we developed and used an IgE-anti-IL-24-specific ELISA to measure serum levels in patients with CSU and healthy control subjects. In combined data from all tested patients with CSU (n 5 1062) and healthy control subjects (n 5 482), the mean 6 SD IgE-anti-IL-24 serum levels were 0.52 6 0.24 IU/mL (median, 0.49 IU/mL; range, 0.00-2.33 IU/mL) and 0.27 6 0.08 IU/mL (median, 0.26 IU/mL; range, 0.10-0.61 IU/mL; P 5.001), respectively (Fig 4) . Eight hundred forty-seven (80%) of 1062 patients with CSU exhibited higher than normal IgE-anti-IL-24 serum levels compared with 99 (20%) of 482 healthy control subjects (P <.0001) based on the calculated cutoff of 0.33 IU/mL. IgE-anti-IL-24 measurement showed acceptable predictive properties for CSU, with a sensitivity of 80% (95% CI, 76% to 83%), a specificity of 80% (95% CI, 75% to 84%), and a likelihood ratio of 3.89 (Fig 4) .
IgE-anti-IL-24 levels in patients with CSU correlate with disease activity
Microarray-based IgE-anti-IL-24 levels correlated with CSU activity, as assessed by using UAS7 (P 5 .03; Fig 5, A) . ELISA-based measurements also showed that relative IgE-anti-IL-24 levels were linked to disease activity, although weakly (Fig 5, B and C) . Relative IgE-anti-IL-24 levels showed a negative association with blood basophil counts (Fig 5, D) .
DISCUSSION
This study shows that patients with CSU produce IgE against a wide array of diverse autoantigens that are distinct from those in patients with IdA and healthy control subjects. Further analyses showed IL-24 to be a common, functional, and specific target of IgE in patients with CSU. These findings support a role for IgE directed to dermal autoantigens, of which IL-24 is the first to be identified, in the pathogenesis of CSU.
This study has performed full-scale screening of IgE autoreactivity in patients with CSU using more than 9000 proteins. Previous studies had identified only single IgE reactivities to self (eg, IgE against thyroperoxidase or DNA) and did not use screening assays for IgE. 5, [12] [13] [14] [15] [16] [17] [18] [19] The present study shows that the IgE of patients with CSU is directed to many more autoantigens than that of healthy control subjects (226 vs 34 autoallergens).
Patients with CSU also exhibit IgE reactivity to a larger set of different autoallergens than patients with IdA, who show similar levels of total IgE as patients with CSU. This supports the conclusion that the IgE reactivities detected are specific rather than artifacts caused by increased total IgE levels. An important question that needs to be addressed by future studies is whether each autoallergen in patients with CSU is detected by one specific IgE or whether there are some IgEs that recognize several autoallergens. Because we cannot answer this question at present, we have assumed in our calculation of IgE-anti-IL-24 levels that all recognized autoallergens are bound by a monospecific IgE. However, because it is possible that IgE-anti-IL-24 is multivalent, in which case only a fraction will be bound to IL-24 in the microarray, this would cause an underestimation of the international units per milliliter level of our IgE-anti-IL-24 results. One thing that is very clear from the Venn diagram (Fig 2) is that the majority of IgEs of patients with CSU, patients with IdA, and healthy control subjects bind to different, group-specific autoallergens. We have explored further only the IgE-AAbs in sera from patients with CSU.
For an IgE-AA to be involved in the pathogenesis of CSU, it would need to both be present in the skin and accessible to mast cell-bound IgE. Eight of 226 IgE-AAs from patients with CSU fulfill these criteria and are therefore likely candidates for causing IgE-dependent skin mast cell activation in patients with CSU. Of these, IL-24 is of prime interest for 3 reasons: (1) IgE against IL-24 is present in the sera of most patients with CSU; (2) IL-24 is present in a soluble form in the skin 20 ; and (3) IgE-anti-IL-24 had the highest serum levels of all IgE-AAbs detected, with about 1% of the total IgE in patients with CSU directed to this cytokine. This 1% level suggests clinical relevance because it is higher than the clinically relevant 0.2% of IgE to b-lactam antibiotics 21 and similar to 1.4% for Cor a 14 and 3.2% for Ara h 2 22 in patients with allergies to these allergens.
A further requisite for IgE-anti-IL-24 to be involved in the pathogenesis of CSU would be its ability to activate mast cells to release histamine. This was confirmed by loading cultured human mast cells with IgE derived from the serum of patients with CSU, followed by challenge with IL-24. The bottom line shows the total number of autoantigens recognized within each group of 7 subjects. The table shows numbers of specific IgE-AAs shared by all patients with CSU (7/7), shared by some patients with CSU (2/7 to 6/7), and found in any of the patients with CSU (1/7). AAs, Autoantigens.
Presently, we do not know and can only speculate whether the biological effects of IL-24, other than being a target of IgE, are relevant in the pathogenesis of CSU. IL-24, an IL-10 family cytokine, 23 has been linked to inflammation 24,25 and described to be upregulated in patients with several autoimmune diseases, such as psoriasis and rheumatoid arthritis. [26] [27] [28] In mouse models of psoriasis, IL-24 is induced by TNF in keratinocytes, and inflammation is dependent on this IL-24 induction. 28, 29 Unlike IL-10, IL-24 is not immunosuppressive but leads to a broad stimulation of various immune cells and functions. 30, 31 In contrast to previous studies, our microarray screen did not identify thyroid peroxidase (TPO) as a common IgE-AA. 5, 12, 32 The reasons for this are currently unclear but might include differences in the glycosylation, folding, or other features of the TPO used or quenching of the IgE-anti-TPO signal in our assay by the presence of IgG-anti-TPO, or it might be that IgE-anti-TPO has a higher affinity to other autoantigens and therefore binds to a different spot on our microarray.
Sir Bradford Hill's 6th criterion for causality states that demonstration of a biological gradient can be associated with increased symptoms. 7 Our finding that IgE-anti-IL-24 levels in patients with CSU, as assessed by using either a microarray or ELISA, are linked to disease activity supports this criterion.
The negative association with blood basophil counts might be the consequence of basophil activation by IgE-anti-IL-24 in the blood. 10, 33 The strength of this study is that it shows a marked increase in IgE-anti-IL-24 values in patients with CSU compared with healthy donors. We used a comprehensive array of autoantigens, included IgE-matched control samples and normal donors to rule out effects that are based on higher total IgE levels and confirmed our microarray results in large populations of patients and healthy control subjects by means of ELISA. A further strength of this study is that it provides ex vivo evidence for the bioactivity of autoreactive IgE and associations with disease activity, both of which suggest pathophysiologic relevance.
A weakness of the study is that we also identified IgEanti-IL-24 in some healthy donors, although at markedly lower concentrations. Other studies have shown that expression of a major anti-FcεRI antibody clone can also be found in healthy donors but does not correlate with any clinical finding.
14,34
Higher IgE-anti-IL-24 serum levels are associated with higher disease activity and lower basophil counts. A, Higher IgE-anti-IL-24 values are linked to higher levels of disease activity, as assessed by using the UAS7 in 5 of the 7 patients with CSU tested by using a microarray (for 2 patients with CSU, no UAS7 score was available). B, Higher levels of relative (to total IgE) IgE-anti-IL-24 tested by means of ELISA are linked to higher disease activity, as assessed by using the UAS7, which reflects disease activity during the 7 days before drawing blood (n 5 52, averaged by pruning from n 5 580 [ie, each data point shown was averaged from 15 original data points for visualization purposes]). C, Higher relative IgE-anti-IL-24 levels, as determined by means of ELISA, are linked to higher CSU disease activity on the day the blood was drawn, as assessed by using the UAS. D, Higher relative IgE-anti-IL-24 levels are associated with lower blood basophil counts. Linear (Fig 5, A-C) and sigmoidal (Fig 5, D) regression lines are shown with 95% CIs as dotted lines.
A further important weakness of this study is that we cannot yet clarify whether IL-24 is the most specific and relevant autoallergen in patients with CSU because we screened only a fraction of the human proteome, with only the major protein variants of each protein included. Also, we calculated the concentration of IgE-anti-IL-24 based on recombinant IgEanti-green fluorescent protein, which might have a much stronger affinity. If IgE binding to IL-24 is only one hallmark of autoreactive IgE and is bound also to other autoallergens on the array, the IgE-anti-IL-24 concentration might be largely underestimated.
In conclusion, IL-24 has been identified as a common, specific, and functional autoantigen of IgE antibodies in patients with CSU. Higher IgE-anti-IL-24 values were associated with higher disease activity. This demonstration of autoreactive IgE in patients with CSU might explain, at least in part, the clinical success of treatment of the disease with the anti-IgE agent omalizumab. New assays for measuring autoreactive IgE, including IgE-anti-IL-24, might help in the clinical management and monitoring of treatment responses in patients with CSU.
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